AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01230983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT01230983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: Given IV
Study NCT01230983 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiation to cranium
Study NCT01230983 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Radiation to cranium
Study NCT02717923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maintenance treatment with capecitabine plus cetuximab
Description: Using a maintenance treatment strategy of capecitabine plus cetuximab as a treatment option in mCRC after first-line 5-FU-based chemotherapy plus cetuximab
Study NCT04315740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Particles from candles
Description: Generating fine and ultrafine particles from lit candles
Study NCT04315740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Particles from cooking
Description: Generating fine and ultrafine particles from frying pork in an oven
Study NCT04315740 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Clean Air
Description: Nothing but clean air
Study NCT01807624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Description: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl (para-butylaminobenzoic acid or PABA is active metabolite)
Study NCT01447459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforced Asthma Education
Description: Before beginning the actual study, a board-certified Asthma Educator (AE) will prepare and administer an asthma education training session for the study personnel, including the PI, the co-investigators, and the study coordinator. The AE will also make herself available via pager for assistance with questions from the study personnel regarding asthma education.~At the end of the administration of the phone surveys (i.e. at 2 weeks, 1 month and 3 months following enrollment), the study coordinator will provide reinforced asthma education to the caregiver via telephone for the subjects enrolled in Group A (the intervention group). The reinforced asthma education will be consistent with the asthma education training session delivered by the AE before the beginning of the study.
Study NCT01443052 — intervention group
Intervention type: OTHER
Intervention: Gait analysis
Description: walking on an electronic walkway GAITRite® at self-selected speed
Study NCT00491634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treosulfan
Description: 12 g/m2 x 3 days
Study NCT00491634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: 12 g/m2 x 3
Study NCT02837770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Eye Drops
Description: One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
Study NCT02837770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pacebo pill
Description: Pacebo pill will be administered 4 hours before the IVI.
Study NCT02837770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Diclofenac
Description: One Diclofenac Sodium sustained-release 75mg tablet administered per os 4 hours prior to the IVI.
Study NCT02837770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pacebo pill
Description: Pacebo pill will be administered 4 hours before the IVI.
Study NCT02837770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial Tears
Description: One drop Artificial Tears will be instilled 45' prior to the IVI.
Study NCT01166282 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab solution for subcutaneous injection.
Study NCT01166282 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo for adalimumab
Description: Placebo for adalimumab solution for subcutaneous injection.
Study NCT04588571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular recanalization with angioplasty and stenting with the biomimetic interwoven nitinol stent
Description: Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion.~Drug therapy includes pre-procedure aspirin (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed aspirin (100 mg per day) for a long time and clopidogrel (75 mg per day) for 3 months.
Study NCT04588571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoropopliteal proximal bypass
Description: Under general anesthesia, 2 standard open surgical approaches are performed: first - to the common femoral artery, superficial femoral artery, and deep femoral artery; the second - to the first portion of the popliteal artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the shunt. Next, the shunt is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Surgical hemostasis wound drainage and layer-by-layer wound closure are performed.~Drug therapy includes pre-procedure aspirin (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed aspirin (75-100 mg per day) for a long time.
Study NCT03183297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMI-001
Description: JMI-001, a combination product of naproxen and fexofenadine
Study NCT03183297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen sodium 220mg
Study NCT03183297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine
Description: Fexofenadine 60mg
Study NCT03183297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo comparator
Study NCT03183297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparator
Study NCT04109261 — intervention group
Intervention type: DRUG
Intervention: Palbociclib
Description: Palbociclib administration in breast cancer patients included in a compassionate use programme. Patients were treated according to the standard of care
Study NCT00531661 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HF Pressure Measurement System
Description: A pressure sensor is intended to be implanted into the pulmonary artery at the time of Swan-Ganz catheterization.
Study NCT00425776 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Study NCT00425776 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Study NCT00811018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Description: Sitaxsentan 100 mg tablets once daily
Study NCT02640534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide 160 mg od until disease progression
Study NCT02640534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide 160 mg od until disease progression
Study NCT02640534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850 mg bid until disease progression
Study NCT04347876 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tuberculin test
Description: Test the delayed hypersensitivity reaction and immunity to previous BCG vaccination
Study NCT02964143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellular Matrix / A-CP HA
Description: Treatment with 2 injections of Cellular Matrix / A-CP HA Kit, administered 2 months apart; Cellular Matrix / A-CP HA Kit is designed for the safe, rapid and extemporaneous preparation of a cellular matrix of autologous PRP combined with HA. The Cellular Matrix / A-CP HA Kit is a single-use medical device including hematology tubes (A-CP HA tube), designed for blood collection and PRP/HA preparation after 5 min centrifugation. This tube contains a non-crosslinked hyaluronic acid (MW 1550 kDa) solution, a gel acting as a cell separator, and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components. The HA, which migrates to the top of the gradient during centrifugation, can be mixed with PRP in order to give rise to a ready-to-use PRP/HA preparation.
Study NCT02964143 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ostenil® Plus
Description: Treatment with 2 injections of Ostenil® Plus, administered one week apart; Ostenil® Plus is a solution of sodium hyaluronate obtained by fermentation, containing 0.5% mannitol, a free radical scavenger, which helps to stabilize the chains of sodium hyaluronate. The product is intended to be used for pain and restricted mobility in degenerative and traumatic changes of the knee joint.
Study NCT02964143 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RegenKit-BCT-1
Description: Treatment with 2 injections of RegenKit-BCT-1, administered 1 month apart; RegenKit-BCT-1 is designed for the safe, rapid and extemporaneous preparation of autologous platelet-rich plasma. RegenKit-BCT-1 is a single-use medical device including an hematology tube (Regen BCT tube), designed for blood collection and PRP preparation after 5 min centrifugation, and all necessary material for venipuncture and PRP injection. The Regen BCT tube contains a gel acting as a cell separator and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components.
Study NCT01170169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole Delayed Release Capsules 40 mg
Study NCT01170169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilosec
Description: Prilosec® 40 mg of Merck \& Co.Inc.
Study NCT00482053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (auto-HSCT)
Description: Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents
Study NCT00482053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Description: Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgrastim (G-CSF)
Study NCT00482053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI)
Description: TLI is administered in 80cGy fractions on Days -11 to Day-7 relative to allo-HSCT
Study NCT00482053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV days 1 and 7 over 4 to 8 hours
Study NCT00482053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Based on body weight, unless its more than 15 kg greater than the idal body 15mg/kg (max dose 550 mg/m2) day -6 over 2 hours.~Males IBW = 50 kg + 2.3 kg/inch over 5 feet Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet Adjusted IBW = IBW + 50% (actual weight - IBW)
Study NCT00482053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 60 mg/kg over 4 hours day -4 and alternatively VP-16 2 Gm/m² may be used (for mobilization)
Study NCT00482053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 10 µg/kg/day subcutaneous starting Day 9 until last day of apheresis. 5 ug/kg actual body weight per day will be started at Day +6 after allo-HCT until hematologic recovery
Study NCT00482053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG)
Description: 1.5 mg/kg/day for 5 days
Study NCT00482053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: 5.0 mg/kg twice daily from day -3 until after day +56
Study NCT00482053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: 250 mg (total) twice daily, oral~15 mg/kg po on day 0, at 5-10 hours after mobilized PBPC infusion is complete. On day +1 MMF is taken at 15 mg/kg po b.i.d. (30 mg/kg/day) if transplantation was using a matched related donor and 15 mg/kg po t.i.d if from a matched unrelated donor or a one antigen mismatched donor.
Study NCT00482053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 100 mg/kg will be administered over 2 hours on day -2
Study NCT00482053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Pre-medication for rituximab and PBPC infusion. Administered at 650 mg by mouth 1 hour prior to infusion
Study NCT00482053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Pre-medication for rituximab and PBPC infusion. Administered at 50 mg intravenous 1 hour prior to infusion
Study NCT00482053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Pre-medication for the PBPC infusion. Administered at 100 mg intravenous 1 hour prior to infusion
Study NCT00482053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Anti-reaction medication for the ATG infusion. Administered at 1 mg/kg, Day-11 to Day-7
Study NCT00345358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix
Description: 1, 2, 3 or 4 Intramuscular injections, depending on age group
Study NCT00345358 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix
Description: 1, 2, 3 or 4 Intramuscular injections, depending on age group
Study NCT00345358 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix IPV/Hib
Description: 4 intramuscular injections
Study NCT04778137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Biological: CMAB007 Biological: Xolair
Study NCT04778137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Biological: CMAB007 Biological: Xolair
Study NCT01385293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120 at the maximum tolerated dose (MTD) of 100mg orally daily
Study NCT06152393 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measure of an antibody index for intrathecal synthesis of specific anti-Treponema pallidum IgG by ELISA.
Description: Paired CSF/serum samples from all patients were blind tested for anti-T. pallidum IgG with an ELISA containing recombinant T. pallidum proteins (Euroimmun).~The AI was calculated conforming to Reiber's method (PMID 11239944) and as previously described in Alberto et al. (PMID 35138118).
Study NCT01574729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surgery combined with rAd-p53 gene therapy
Description: Surgery combined with rAd-p53 gene therapy during surgery plus post-surgery chemotherapy
Study NCT01574729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery plus post-surgery chemotherapy
Study NCT01070485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 chloride (BAY88-8223)
Description: The required volume of study drug to be administered to a patient was calculated using the patient's body weight (50 kBq/kg b.w.).
Study NCT01877395 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified Vero Rabies Vaccine (VRVg)
Description: 0.5 mL, Intramuscular
Study NCT01877395 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imovax® Rabies: inactivated rabies vaccine
Description: 1.0 mL, Intramuscular
Study NCT03657082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEP-10
Description: Bottle PEP with a water level of 10 cmH2O
Study NCT03657082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEP-1
Description: Bottle PEP with a water level of 1 cmH2O
Study NCT01012440 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEM Flex Solo II PET Scanner
Description: Subjects will receive bilateral (both sides) breast and axillary PEM scans.
Study NCT01012440 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: Subjects will receive bilateral (both sides) breast and axillary MRI scans.
Study NCT02304367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Burosumab
Description: Solution for subcutaneous injection
Study NCT04467372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tart cherry juice concentrate
Description: Two 8oz bottles of tart cherry juice concentrate daily for 30 days
Study NCT04467372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juice placebo
Description: Two 8oz bottles of placebo juice daily for 30 days
Study NCT04467372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freeze dried tart cherry powder
Description: Two freeze dried tart cherry powder capsules daily for 30 days
Study NCT04467372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsule placebo
Description: Two placebo capsules daily for 30 days
Study NCT01525069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Study NCT01525069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT01525069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT01525069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT01760252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)
Description: Neoadjuvant CAPOXIRI chemotherapy is an innovative strategy that builds on the advancement associated with FOLFIRINOX chemotherapy in patients with metastatic disease
Study NCT04200599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: duration of initiation of oxytocin
Description: mode of delivery
Study NCT04200599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: duration of initiation of oxytocin
Description: mode of delivery
Study NCT02784899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloprost
Description: 20μg(2ml) of inhaled iloprost (Ventavis®)~When anesthesia induction finishes, change patients' position from supine to lateral position and measure arterial blood gas analysis (ABGA), venous blood gas analysis (VBGA) while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished.
Study NCT02784899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 20μg(2ml) of inhaled normal saline~When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished.
Study NCT04454918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906 Oral Capsule
Description: TAK-906 capsule.
Study NCT04454918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-TAK-906 Intravenous Infusion
Description: \[14C\]-TAK-906 intravenous infusion.
Study NCT04454918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-TAK-906 Oral Solution
Description: \[14C\]-TAK-906 oral solution.
Study NCT04055077 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-flow nasal oxygenation (LFNO) ASA I
Description: Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
Study NCT04055077 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-flow nasal oxygenation (LFNO) ASA II
Description: Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
Study NCT04055077 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-flow nasal oxygenation (LFNO) ASA III
Description: Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
Study NCT04055077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygenation (HFNO) ASA I
Description: Experimental HFNO: O2 flow 40 L/min, FiO2 40%
Study NCT04055077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygenation (HFNO) ASAII
Description: Experimental HFNO: O2 flow 40 L/min, FiO2 40%
Study NCT04055077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygenation (HFNO) ASA III
Description: Experimental HFNO: O2 flow 40 L/min, FiO2 40%
Study NCT00624598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART
Description: Use of measured resting metabolic rate from indirect calorimetry for personalized diet program and use of a computer application for journalizing food and exercise.